Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1925-1935
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1925
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1925
Table 2 Comparison of short-term efficacy
| Indicator | Observation group, n = 46 | Control group, n = 46 | χ2 | P value |
| Complete response | 11 (23.91) | 5 (10.87) | ||
| Partial response | 24 (52.17) | 18 (39.13) | ||
| Stable disease | 7 (15.22) | 20 (43.48) | ||
| Disease progression | 4 (8.70) | 3 (6.52) | ||
| Overall response | 35 (76.09) | 23 (50.00) | 6.718 | 0.010 |
- Citation: Feng R, Cheng DX, Chen XC, Yang L, Wu H. Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer. World J Gastrointest Oncol 2023; 15(11): 1925-1935
- URL: https://www.wjgnet.com/1948-5204/full/v15/i11/1925.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i11.1925